Mine UYANIK, Orkun Tahir ARAN, Sedef ŞAHİN, Meral HURİ

Cross-cultural adaptation, reliability, and validity of the Turkish version of the Cancer Fatigue Scale in patients with breast cancer

Background/aim: The Cancer Fatigue Scale (CFS) was developed to evaluate the severity of fatigue in patients with breast cancer. Theaim of this study is to translate and culturally adapt a Turkish version and investigate the validity and reliability of the CFS in Turkishpatients with fatigue symptoms.Materials and methods: Eighty participants completed the Turkish version of the CFS for breast cancer and the European Organizationfor Research and Treatment of Cancer Quality of Life Core Questionnaire “Core 30” (EORTC QLQ-C30). Test–retest reliability wasevaluated by repeating the CFS with a 7-day interval.Results: The CFS demonstrated high test–retest reliability (ICC = 0.95) and good internal consistency (Cronbach’s alpha = 0.74) for alldomains. The Kaiser–Meyer–Olkin measure of sampling adequacy was found to be 0.819, which is considered to be satisfactory (>0.5).Correlations between domains of CFS physical and EORTC physical (r: 0.77), CFS cognitive and EORTC cognitive (r: 0.70), and CFSphysical and EORTC fatigue (r: 0.80) were found to be significant.Conclusion: The Turkish version of the CFS is a reliable and valid instrument to assess physical, effective, and cognitive dimensions offatigue. The CFS may be used to evaluate the severity of fatigue in Turkish-speaking breast cancer patients.

PDF

___

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Cancer-Related Fatigue and Anemia. Version I. Fort Washington, PA, USA: NCCN; 2014.
Minton O, Stone P. How common is fatigue in diseasefree breast cancer survivors? A systematic review of the literature. Breast Cancer Res Tr 2008; 112: 5-13.
Ganz PA, Bower JE. Cancer related fatigue: a focus on breast cancer and Hodgkin’s disease survivors. Acta Oncol 2007; 46: 474-479.
Goedendorp MM, Gielissen MFM, Verhagen CAH, Peters MEJW, Bleijenberg G. Severe fatigue and related factors in cancer patients before the initiation of treatment. Brit J Cancer 2008; 99: 1408-1414.
Abrahams HJ G, Gielissen MFM, Schmits IC, Verhagen CAHHVM, Rovers MM, Knoop H. Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors. Ann Oncol 2016; 27: 965-974.
Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer-related fatigue: a critical appraisal. Eur J Cancer 2006; 42: 846-863.
Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Ogaily MS. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol 2014; 32: 1840-1850.
Schneider RA. Reliability and validity of the Multidimensional Fatigue Inventory (MFI-20) and the Rhoten Fatigue Scale among rural cancer outpatients. Cancer Nurs 1998; 21: 370- 373.
Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 1998; 25: 677-684.
Smets EMA, Garssen B, Bonke BD, De Haes JCJM. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychiat Res 1995; 39: 315-325.
Okuyama T, Akechi T, Kugaya A, Okamura H, Shima Y, Maruguchi M, Uchitomi Y. Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manag 2000; 19: 5-14.
Okuyama T, Akechi T, Kugaya A, Okamura H, Imoto S, Nakano T, Uchitomi Y. Factors correlated with fatigue in disease-free breast cancer patients: application of the Cancer Fatigue Scale. Support Care Cancer 2000; 8: 215-222.
Ünsal D, Aksu A, Bağrıaçık Ü, Akmansu M. Postmastektomi radyoterapi uygulanan meme kanserli olgularda gelişen yorgunluğun derecesi, serum sitokin ve leptin düzeyleri ile ilişkisi: prospektif değerlendirme. Turkish Journal of Oncology 2007; 22: 1-12 (in Turkish).
Kröz M, Zerm R, Reif M, Von Laue HB, Schad F, Büssing A, Girke M. Validation of the German version of the Cancer Fatigue Scale (CFS‐D). Eur J Cancer Care 2008; 17: 33-41.
Montazeri A, Haghighat S, Ebrahimi M. The Cancer Fatigue Scale (CFS): translation and validation study of the Iranian version. Qual Life Res 2005; 14: 2132.
Shun SC, Beck SL, Pett MA, Berry PH. Psychometric testing of three Chinese fatigue instruments in Taiwan. J Pain Symptom Manag 2006; 32: 155-167.
Charalambous A, Kaite C, Constantinou M, Kouta C. Translation and validation of the Cancer-Related Fatigue Scale in Greek in a sample of patients with advanced prostate cancer. BMJ Open 2016; 6: e011798.
Guzelant A, Goksel T, Ozkok S, Tasbakan S, Aysan T, Bottomley A. The European Organization for Research and Treatment of Cancer QLQ-C30: an examination into the cultural validity and reliability of the Turkish version of the EORTC QLQ-C30. Eur J Cancer Care 2004; 13: 135-144.
Pınar G, Algier L, Çolak M, Ayhan A. Jinekolojik kanserli hastalarda yaşam kalitesi. International Journal of Hematology and Oncology 2008; 3: 141-149 (in Turkish).
Beaton DE, Bombardier C, Guillemin F, Ferraz MB. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine 2000; 25: 3186-3191.
Kimberlin CL, Winetrstein AG. Validity and reliability of measurement instruments used in research. Am J Health-Syst Ph 2008; 65: 23.
George D, Mallery P. SPSS for Windows Step by Step: A Simple Guide and Reference. 11.0 Update. 4th ed. Boston, MA, USA: Allyn & Bacon; 2003.
Knobel H, Loge JH, Brenne E, Fayers P, Hjermstad MJ, Kaasa S. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors. Palliat Med 2003; 17: 664-672.
Okuyama T, Wang XS, Akechi T, Mendoza TR, Hosaka T, Cleeland CS, Uchitomi Y. Validation study of the Japanese version of the brief fatigue inventory. J Pain Symptom Manag 2003; 25: 106-117.
Raudonis BM, Kelley IH, Rowe N, Ellis J. A pilot study of proinflammatory cytokines and fatigue in women with breast cancer during chemotherapy. Cancer Nurs 2017; 40: 323-331.